Eli Lilly and Company (LLY)
Pre-Market:
| Previous Close | 734.97 |
| Open | 738.04 |
| Bid | 762.10 x 1200 |
| Ask | 766.67 x 900 |
| Day's Range | 736.00 - 766.99 |
| 52 Week Range | 419.80 - 800.78 |
| Volume | |
| Avg. Volume | 2,938,421 |
| Market Cap | 728.657B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 112.42 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 5.20 (0.68%) |
| Ex-Dividend Date | May 15, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
